2-Chloro-deoxyadenosine Induces Durable Complete Remission in Castleman's Disease but may Accelerate its Transformation to Non-Hodgkin's Lymphoma

Acta Oncologica

Volumn 42, Issue 7, 2003, Pages 784-787

  Colleoni, Gisele W B ^a,c   Duarte, Luiz Cláudio C ^a   Kerbauy, Fábio Rodrigues ^a   Lobão, Marcos ^a   Yunis, Melissa Palis ^a   Correa Alves, Antonio ^a   De Souza, Vanda Akiko Ueda Fick ^b   Bordin, José Orlando ^a   De Oliveira, José Salvador R ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Hematologia   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; DISEASE CONTROL; DISEASES; IMMUNOLOGY; PATIENT MONITORING;

IMMUNE SYSTEMS; NEOPLASMS;

ONCOLOGY;

CHLORAMBUCIL; CISPLATIN; CLADRIBINE; CYCLOSPORIN; DEXAMETHASONE; ETOPOSIDE; IFOSFAMIDE; IMMUNOGLOBULIN; MESNA; MITOXANTRONE; PREDNISOLONE;

ADULT; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; B CELL LYMPHOMA; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CASE REPORT; DISEASE COURSE; DISEASE EXACERBATION; ERYTHEMA MULTIFORME; FEMALE; HUMAN; IMMUNE DEFICIENCY; IMMUNE SYSTEM; LARGE CELL LYMPHOMA; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; T CELL LYMPHOMA; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; CLADRIBINE; FEMALE; GIANT LYMPH NODE HYPERPLASIA; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 0344155178     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860310003527     Document Type: Article

References (16)

1. Castleman B, Iverson L, Menendez VP. Localized mediastinal lymph-node hyperplasia resembling thymoma. Cancer 1956; 9: 822-30.
2. Keller AR, Hochholzer L, Castleman. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 1972; 29: 670-83.
3. Bowne WB, Lewis JJ, Filippa DA, et al. The management of unicentric and multicentric CD. A report of 16 cases and review of the literature. Cancer 1999; 85: 706-17.
4. Larroche C, Cacoub P, Soulier J, et al. Castleman's disease and lymphoma: report of eight cases in HIV-negative patients and literature review. Am J Hematol 2002; 69: 119-26.
5. Ming-Qing D, Liu H. Diss TC, et al. Kaposi sarcoma-associated herpesvirus infects monotypic (IgM) but polyclonal naive B-cells in Castleman disease and associated lymphoproliferative disorders. Blood 2001; 97: 2130-6.
6. Oksenhendler E, Carcelain G, Aoki Y, et al. High levels of human herpesvirus 8 viral load, human IL-6, IL-10, and C-reactive disease in HIV-infected patients. Blood 2000; 96: 2069-73.
7. Chronowski GM, Ha CS, Wilder RB, Cabanillas F, Manning J, Cox JD. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer 2001; 92: 670-6.
8. Beck JT, Hsu SM, Wijdenes J, et al. Alleviation of systemic manifestations of CD by monoclonal anti-interleukin-6 antibody. Neth J M 1994; 330: 602-5.
9. Bordeleau L, Bredeson C, Markman S. 2-chloro-deoxyadenosine therapy for giant lymphnode hyperplasia. Br J Haematol 1995; 91: 668-70.
10. Corbellino M, Bestetti G, Scalamogna C, et al. Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood 2001; 98: 3473-5.
11. Fisher RI, Gaynor ER, Dhalberg S, et al. Comparison of standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002-6.
12. Rodriguez MA, Cabanillas FC, Velasquez W, Hagemeister FB, McLaughlin P, Swan F, Romanguera. Results of salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol 1995; 13: 1734-41.
13. Weisenburger DD, Nathawani BN, Winberg CD, Rappaport H. Multicentric angiofollicular lymph node hyperplasia: a clinico-pathologic study of 16 cases. Hum Pathol 1985; 16: 162-72.
14. Weiss GR, Kuhn JG, Rizzo J, 3rd, Fields S, VanDenBerg K, von Hoff DD. A phase I and pharmacokinetics study of 2-chlorodeoxyadenosine in patients with solid tumors. Cancer Chemother Pharmacol 1995; 35: 397-402.
15. Van Den Neste E, Delannoy A, Feremans W, Ferrant A, Michaux L. Second primary tumors and immune phenomena after fludarabine or 2-chloro-2′- deoxyadenosine treatment. Leuk Lymphoma 2001; 40: 541-50.
16. Robak T, Urbanska-Rys H, Strzelecka B, et al. Plasmablastic lymphoma in a patient with chronic lymphocytic leukemia heavily pretreated with cladribine (2-CdA): an unusual variant of Richter's syndrome. Eur J Haematol 2001; 67: 322-7.